The U.S. Food and Drug Administration has approved a supplemental Biologics License Application for a subcutaneous form of lecanemab, branded as LEQEMBI IQLIK, for the treatment of early Alzheimer's disease, Eisai Co., Ltd. and Biogen Inc. announced. This approval introduces a once-weekly, at-home administration option via an autoinjector, offering a convenient alternative to intravenous dosing from the start of treatment. […]















